The science behind Aromha is built on over 20 years of olfactory research at Massachusetts General Hospital and Harvard Medical School by our co-founder and neurologist, Dr. Mark Albers. We are also backed by $11M+ in National Institute of Health (NIH) grants and have executed multiple successful clinical trials.

Olfactory Dysfunction

Olfactory dysfunction (i.e. the loss of the sense of smell) is increasingly recognized as a significant health concern. Research suggests a strong association between a declining sense of smell and various health issues, including increased mortality, systemic inflammation, and neurodegenerative diseases like Alzheimer’s.

Towards universal chemosensory testing: needs, barriers, and opportunities Steven D. Munger, Kai Zhao, Linda A. Barlow, Duncan Boak, Katie Boateng, Susan E. Coldwell, Pamela Dalton, Richard L. Doty, Jennifer E. Douglas, Valerie Duffy, Frank A. Franklin, John E. Hayes, Howard J. Hoffman, Patrice Hubert, Paule V. Joseph, Jeb M. Justice, Joshua M. Levy, Julie A. Mennella, Marianna Obrist, M. Yanina Pepino, Jayant M. Pinto, Edmund A. Pribitkin, Christopher T. Simons, Mark W. Albers, Valentina Parma

Association of Olfactory Impairment With All-Cause Mortality: A Systematic Review and Meta-analysis

NatalieYan-Lin Pang, Harris Jun Jie, Muhammad Danial Song, Benjamin Kye Jyn Tan, Jun Xiang Tan, Ashley Si Ru Chen, Anna See, MRCS, MMed(ORL), Shuhui Xu, MMed(ORL), Tze Choong Charn, MMed(ORL), FEBE(ORL), Neville Wei YangTeo, MRCS, MMed(ORL)

Olfactory Dysfunction Predicts 5-Year Mortality in Older Adults

Jayant M Pinto , Kristen E Wroblewski , David W Kern , L Philip Schumm , Martha K McClintock

Inflammation and olfactory loss are associated with at least 139 medical conditions

Michael Leon , Emily T. Troscianko , Cynthia C. Woo

Rapid olfactory decline during aging predicts dementia and GMV loss in AD brain regions Rachel R Pacyna, S Duke Han, Kristen E Wroblewski, Martha K McClintock, Jayant M Pinto

Olfactory Dysfunction as a Global Biomarker for Sniffing out Alzheimer’s Disease: A Meta-Analysis Alisha M Kotecha, Angelo D C Corrêa, Kim M Fisher, Jo V Rushworth

Odor identification and progression to dementia: The role of odor characteristics and set size Eva Dickmänken, Maria Larsson, Ingrid Ekström, Jonas Olofsson, Giulia Grande, Debora Rizzuto, Erika J. Laukka

At the interface of sensory and motor dysfunctions and Alzheimer’s disease Mark W Albers , Grover C Gilmore , Jeffrey Kaye , Claire Murphy , Arthur Wingfield , David A Bennett , Adam L Boxer , Aron S Buchman , Karen J Cruickshanks , Davangere P Devanand , Charles J Duffy , Christine M Gall , George A Gates , Ann-Charlotte Granholm , Takao Hensch , Roee Holtzer , Bradley T Hyman , Frank R Lin , Ann C McKee , John C Morris , Ronald C Petersen , Lisa C Silbert , Robert G Struble , John Q Trojanowski , Joe Verghese , Donald A Wilson , Shunbin Xu , Li I Zhang

Olfactory and cognitive decrements in 1991 Gulf War veterans with gulf war illness/chronic multisymptom illness Linda L Chao

Olfactory function and discrimination ability in the elderly: a pilot study Sae Uchida , Chiho Shimada , Naoko Sakuma , Fusako Kagitani , Akiko Kan , Shuichi Awata

The Aromha Brain Health Test

Beyond the impact of olfactory dysfunction on quality of life, research suggests a strong link between olfactory dysfunction and cognitive impairment. Aromha offers a scientifically tested non-invasive at-home test for olfactory loss.

AROMHA Brain Health Test: A Remote Olfactory Assessment as a Screen for Cognitive Impairment Benoît Jobin, Colin Magdamo, Daniela Delphus, Andreas Runde, Sean Reineke, Alysa Alejandro Soto, Beyzanur Ergun, Alefiya Dhilla Albers, Mark W Albers

Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly Alefiya Dhilla Albers , Josephine Asafu-Adjei , Mary K Delaney , Kathleen E Kelly , Teresa Gomez-Isla , Deborah Blacker , Keith A Johnson , Reisa A Sperling , Bradley T Hyman , Rebecca A Betensky , Lloyd Hastings , Mark W Albers

Dementia Prevention & Intervention

The disparity in early detection of cognitive impairment continues to be a challenge. Furthering the rising burden of Alzheimer’s disease (AD) is astounding cost to develop disease-modifying therapies. At the same time stronger evidence is emerging on risk factors contributing to dementia creating a need for timely, equitable, scalable, and sustainable detection approaches.

Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission

Gill Livingston, Jonathan Huntley, Kathy Y Liu, Sergi G Costafreda, Geir Selbæk, Suvarna Alladi, David Ames, Sube Banerjee, Alistair Burns, Carol Brayne, Nick C Fox, Cleusa P Ferri, Laura N Gitlin, Robert Howard, Helen C Kales, Mika Kivimäki, Eric B Larson, Noeline Nakasujja, Kenneth Rockwood, Quincy Samus, Kokoro Shirai, Archana Singh-Manoux, Lon S Schneider, Sebastian Walsh, Yao Yao, Andrew Sommerlad, Naaheed Mukadam

Population Attributable Fraction of Incident Dementia Associated With Hearing Loss Emily Ishak , Emily A Burg , James Russell Pike , Pablo Martinez Amezcua , Kening Jiang , Danielle S Powell , Alison R Huang , Jonathan J Suen , Pamela L Lutsey , A Richey Sharrett , Josef Coresh , Nicholas S Reed , Jennifer A Deal , Jason R Smith

The costs of developing treatments for Alzheimer’s disease: A retrospective exploration Jeffrey L Cummings , Dana P Goldman , Nicholas R Simmons-Stern , Eric Ponton

Prevalence of Unrecognized Cognitive Impairment in Federally Qualified Health Centers

Ambar Kulshreshtha, Erik S.Parker, Nicole R.Fowler, Diana Summanwar, Zina Ben Miled, Arthur H.Owora, James E.Galvin, Malaz A.Boustani

Multi-modal Biomarkers

Imaging, Cerebrospinal fluid, and blood biomarkers provide diagnostic means to detect Alzheimer’s and related dementia. However, they are utilized after symptoms appear and can be costly and/or invasive. Cognition and olfactory assessments provide a cost effective and non-invasive means to detect impairment comparable to imaging. In addition to the olfactory screen, Aromha utilize a multi-modal approach including imaging and blood biomarkers to obtain a higher fidelity signal.

Comparison of brief olfactory and cognitive assessments to neuroimaging biomarkers in the prediction of cognitive decline and dementia in the MCSA cohort

Davangere P. Devanand, Seonjoo Lee, José A. Luchsinger, David Knopman, Maria Vassilaki, Jeffrey N. Motter

Expanding the use of brief cognitive assessments to detect suspected early-stage cognitive impairment in primary care Soeren Mattke, Donnie Batie, Joshua Chodosh, Kristen Felten, Ellen Flaherty, Nicole R Fowler, Fred A Kobylaz, Kelly O Brien, Russ Paulsen, Anne Pohnert, Katherine L Possin, Tatiana Sadak, Diane Ty, Amy Walsh, Julie M Zissimopoulos

Blood protein markers predict 15-year risk of dementia Yu Guo & Jin Tai Yu